All In Biotech

BLA 761444 · Shanghai Henlius Biotech

Bilprevda

Denosumab-Nxxp · Injection · RANK Ligand Inhibitor

Last checked: Nov 20, 2026Latest source record: Oct 29, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Aug 29, 2025

Approved uses

2

Original approval plus efficacy supplements

Registered trials

287

81 Phase 3, 26 recruiting

FAERS reports

16,625

15,968 serious, 1,943 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 18, 2026.

Bilprevda is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) 1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors Bilprevda is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. 1.2 Giant Cell Tumor of Bone Bilprevda is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see Clinical Trials ( 14.2 )] . 1.3 Hypercalcemia of Malignancy Bilprevda is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

Mechanism: Denosumab products bind to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption, thereby modulating calcium release from bone. Increased osteoclast activity, stimulated by RANKL, is a mediator of bone pathology in solid tumors with osseous metastases.Similarly, giant cell tumors of bone consist of stromal cells expressing RANKL and osteoclast-like giant cells expressing RANK receptor, and signaling through the RANK receptor contributes to osteolysis and tumor growth. Denosumab products prevent...

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • BILPREVDA · DENOSUMAB-NXXP 120MG/1.7ML(70MG/ML) · INJECTABLE, INJECTION · Prescription
  • BILDYOS · DENOSUMAB-NXXP 60MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Denosumab" as an intervention, any sponsor and status, largest first.

All 287 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • osteonecrosis of jaw1,555
  • diarrhoea1,177
  • fatigue1,139
  • nausea1,088
  • malignant neoplasm progression1,072
  • neutropenia981
  • metastases to bone857
  • off label use847
  • anaemia758
  • vomiting619
  • dyspnoea609
  • hypocalcaemia608

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20092
201067
2011136
2012214
2013358
2014474
2015662
2016748
2017636
2018956
20191,013
20201,063
20211,495
20221,772
20231,781
20241,728
20251,749
20261,770

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 725 on PubMed

Sponsor: Shanghai Henlius Biotech · Also marketed as Bildyos

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.